Digital Health Evaluation Checklist for Payers

A practical checklist for payers to assess digital therapeutics and AI vendors on evidence, equity, interoperability, ROI and contract safeguards.

Digital health procurement has moved from experimentation to operational necessity. Health plans, delegated risk entities, and population health teams are now being asked to decide which digital therapeutics, remote monitoring platforms, conversational AI tools, and care-navigation products deserve a place in the clinical and financial operating model. The challenge is that many vendors present compelling demos, but only a subset can prove clinical benefit, improve equity, integrate cleanly with core systems, and deliver measurable ROI at scale. That makes digital health evaluation less of a technology selection exercise and more of a disciplined population health decision process. For teams that want a practical starting point, it helps to borrow from proven vendor-selection frameworks like how to choose a digital marketing agency with an RFP and scorecard and adapt them for healthcare’s higher bar for evidence and safety.

This guide gives payers and population health leaders a definitive checklist to assess digital health tools before contracting. It is built around the questions that matter most in managed care: Does the product work, for whom, under what conditions, and at what cost? Can it exchange data reliably with EHRs, claims systems, member portals, and care management platforms? Is it accessible to members with limited digital literacy, language barriers, disabilities, or unstable connectivity? And what contractual guardrails prevent expensive surprises after go-live? To evaluate these tools well, leaders need the same rigor used in other operational decisions, whether they are choosing whether to operate or orchestrate a portfolio decision or designing a repeatable review cycle like when to upgrade your tech review cycle.

1) Start With the Use Case, Not the Demo

Define the population problem in plain language

The most common mistake in digital health procurement is buying a solution before defining the problem. A plan that wants to reduce avoidable ED visits for members with heart failure is solving a different problem than an employer group trying to expand low-acuity behavioral health access or a Medicaid plan trying to improve prenatal engagement. The right tool for one use case may be a poor fit for another, even if the vendor’s platform appears broadly capable. Population health leaders should translate the business need into a single sentence that identifies the target population, desired behavior change, and success metric. That discipline is similar to the way strong market teams scope a campaign before buying services, as described in vendor RFP scorecards.

Separate engagement goals from outcome goals

Engagement is not the same as clinical impact. Many tools can generate clicks, logins, and message reads, but those are intermediate measures that may or may not affect admissions, adherence, A1c, blood pressure, PHQ-9 scores, or total cost of care. Leaders should ask whether the tool is intended to change behavior, support care coordination, automate a workflow, or detect risk earlier. If the objective is simply to engage members, the vendor can be scored on activation and retention. If the goal is a medical outcome, then the evaluation should require evidence that outcomes actually change in the intended population.

Document the decision horizon and accountability model

Before scoring vendors, decide who owns the outcome window. Some programs should be evaluated over 90 days, such as post-discharge outreach or medication reminders, while others need 6 to 12 months, like diabetes management or musculoskeletal digital therapeutics. You also need to know whether the business owner is medical management, care management, pharmacy, behavioral health, or the actuarial team. In one mature model, a health plan may use a triage process similar to competitive intelligence techniques to understand the market, then route only high-fit tools into pilot design. That prevents pilot sprawl and protects operational bandwidth.

2) Require Clinical Validation That Matches the Claim

Match the evidence type to the product category

Not all digital health tools need the same level of proof, but all need evidence proportional to their claims. A wellness app should not be held to the same evidentiary threshold as a prescription digital therapeutic, yet neither should be selected purely on marketing language. Ask whether the product has been evaluated in randomized trials, pragmatic studies, observational cohorts, or internal pre-post analyses, and whether the study population resembles your members. A vendor selling behavioral health automation should not rely on thin engagement metrics if the product claims to reduce symptoms or utilization. The credibility standard should resemble the rigor used to assess other evidence-heavy products, such as home-use light therapy, where indications, safety, and appropriate use matter more than promotional claims.

Look for comparator quality and real-world generalizability

Ask what the tool was compared against. A pre-post design without a comparator can overstate benefit because regression to the mean, seasonal variation, and concurrent care changes may explain the observed improvement. Better evidence includes randomized or matched comparisons, with results reported for both responders and non-responders. Population health teams should also examine whether the study included commercially insured adults only, or whether it included older adults, Medicaid enrollees, rural residents, multilingual populations, and people with low digital confidence. Digital health often works best under ideal circumstances, but payers need to know whether it works in the messy reality of day-to-day care delivery.

Demand subgroup and safety data, not only top-line results

Any vendor can produce a headline result. Stronger vendors show who benefited, who did not, and whether any harms or dropout patterns emerged. Leaders should request subgroup analyses by age, race and ethnicity, language preference, disability status, geography, and baseline risk when available. If a tool depends on smartphone use, app permissions, connected devices, or frequent self-reporting, its drop-off pattern matters as much as its average effect size. In practice, this is no different than checking the failure modes of a technology before rollout, much like teams reading predictive maintenance guidance for websites to understand downtime risk before launching a digital asset.

3) Evaluate Equity Impact as a Core Selection Criterion

Ask who is excluded by design

Equity review should happen before procurement, not after launch. A digital health tool may be clinically promising but practically inaccessible to members who lack stable internet, have low literacy, use older devices, or prefer oral rather than written communication. Population health leaders should assess whether the product supports multilingual content, closed-captioned video, screen-reader compatibility, low-bandwidth mode, caregiver access, and offline or SMS-based workflows. The vendor should be able to explain how the tool performs in populations that have historically lower digital engagement. A plan cannot claim health equity improvement while deploying a product that implicitly serves only the most digitally advantaged members.

Require equity-specific performance metrics

Do not accept “overall engagement” as proof of fair access. Ask vendors to report activation, retention, adherence, and outcome differences across demographic and social risk strata. If a product improves outcomes overall but widens the gap between advantaged and disadvantaged members, it may be net harmful at the population level. Leaders should also ask whether the vendor has run usability testing with members who have limited health literacy, limited English proficiency, sensory limitations, or cognitive impairment. In the same way that adaptive learning tools for science education must bridge accessibility gaps to be truly useful, digital health tools must prove they can reach the people who are hardest to engage.

Build community and caregiver realities into scoring

Many care plans are made in households, not just in apps. Caregiver participation, shared decision-making, and family support can determine whether a digital tool gets used consistently. Payers should ask whether the platform allows caregiver permissions, shared reminders, proxy scheduling, or multi-language workflows. They should also consider whether the intervention respects local context and reduces administrative burden for community health workers, care navigators, or health coaches. If equity is measured only at the point of login, leaders will miss the practical barriers that determine whether the intervention can work at scale.

4) Make Interoperability a Hard Gate, Not a Nice-to-Have

Test the data flow from intake to action

Interoperability is not just an IT preference; it determines whether digital health tools create coordinated care or extra work. Leaders should map the full data journey: how a member is identified, how eligibility is determined, how the tool exchanges enrollment data, how alerts are sent, and how outcomes are written back to the plan’s systems. If the vendor cannot connect with claims, care management platforms, or EHR workflows through standards-based APIs and secure interfaces, the result is likely manual reconciliation and low adoption. Health systems have already learned that interoperability-first thinking avoids downstream friction, as explained in the interoperability playbook for wearables and remote monitoring.

Check compatibility with your existing stack

Not every tool needs the same integration depth, but every tool needs a defined operating model. Some solutions should integrate with FHIR-based APIs, SSO, patient identity tools, claims feeds, or referral platforms. Others may need only secure exports for analytics and operational reporting. Population health leaders should involve IT, security, analytics, care management, and compliance teams early so they can confirm what data are required and what data are optional. A vendor that cannot support the organization’s architecture often becomes a shadow workflow, which erodes trust and makes outcomes impossible to attribute accurately.

Measure interoperability by operational burden

A useful question is not “Can it integrate?” but “How much work does the integration still create?” If care coordinators must manually import lists, reconcile member identities, or interpret alerts that arrive too late, the tool may be technically connected but functionally broken. Ask for implementation timelines, interfaces supported, error-handling processes, and examples of production use in similar payer environments. Then test the vendor’s promise against the real-world operating cost. Even consumer technology teams understand this logic when they evaluate features that reduce team friction; healthcare should demand at least that much operational clarity.

5) Assess AI and Algorithmic Tools With a Safety Lens

Demand model transparency proportional to risk

AI tools used in utilization management, care management, risk stratification, outreach prioritization, or symptom triage should be evaluated with more scrutiny than generic software. Leaders should ask what inputs drive the model, how often it is retrained, how drift is detected, and whether human override is possible. If the vendor cannot explain the model’s intended function and failure modes in plain language, that is a warning sign. AI in health should be treated as a decision-support layer, not an unchallengeable authority. The same caution used in evaluating complex technology supply chains applies here; if a component is opaque, the risk can cascade quickly, as seen in discussions of AI supply chain disruption.

Validate against your member population

An AI model may perform well in a vendor’s benchmark environment and poorly in your population because of different demographics, coding patterns, benefit design, or utilization patterns. Population health leaders should insist on validation using their own data, or at minimum a close proxy dataset, before scale-up. Evaluate calibration, false positives, false negatives, and subgroup performance. If a model prioritizes outreach to members already engaged with care and misses high-need but hard-to-reach members, it may reinforce inequity while appearing efficient. That is why model performance must be judged against downstream actions and outcomes, not just statistical scores.

Require human factors review and escalation logic

Even when AI is accurate, it can still fail through workflow design. Staff must know when to trust the output, when to disregard it, and how to escalate uncertain cases. A strong vendor should show how the tool supports rather than overwhelms care teams, and how the interface prevents automation bias. This is where health plans can borrow from other domains that use layered review and exception handling, similar to a structured in-app feedback loop that captures real user behavior rather than relying on one metric alone.

6) Build a Procurement Scorecard That Forces Tradeoffs

Weight evidence, fit, and implementation separately

Procurement teams often collapse very different questions into a single vendor pitch score. That approach hides tradeoffs and makes it difficult to distinguish a product that is impressive in demos from one that is operationally sound. A better scorecard gives separate weights to clinical evidence, equity, interoperability, workflow fit, security, and commercial terms. Population health leaders should also score the vendor’s implementation maturity, customer support quality, and willingness to provide data access. This mirrors the discipline used in business procurement and supplier selection, similar to smart sourcing with data platforms or timing decisions using buyer insights.

Create a red-flag list that automatically disqualifies vendors

Some issues should end the conversation immediately. Examples include refusal to share study methodology, inability to identify data ownership terms, lack of security documentation, no plan for member consent, no accommodation for accessibility needs, and no clear rollback strategy if the product underperforms. Vendors that overpromise on ROI without defining the baseline and attribution method should also be treated cautiously. A disciplined red-flag list protects the organization from persuasive sales narratives and keeps procurement centered on member impact. In consumer contexts, people are taught to look for quality signals before purchase, just as shoppers learn from practical buyer’s guides rather than glossy advertising.

Insist on references from similar buyer types

A product used by an employer group or a provider system may not behave the same way in a Medicaid or Medicare Advantage population. Leaders should ask for references that resemble their own benefit design, demographic mix, and implementation complexity. Talk to operational users, not only executive sponsors. Ask what took longer than expected, what data issues arose, and what they would change in the contract. In many cases, the strongest signal comes from how the vendor behaves after the sale, not during the demo.

7) Measure ROI With a Method That Survives Scrutiny

Pick primary and secondary outcomes before launch

Too many digital health pilots fail because the team never agreed on what success would mean. Leaders should define one primary clinical or utilization outcome and a small set of secondary operational metrics before implementation. Examples include avoidable admissions, ED visits, medication adherence, time to outreach, completion of recommended care, patient-reported outcomes, or staff time saved. Without pre-specified measures, every result looks favorable to someone. For a deeper view on how outcome framing affects business decisions, read about metrics and storytelling used by investment-ready market leaders.

Use attributable and non-attributable cost categories

ROI measurement should separate direct vendor fees from implementation costs, internal labor, integration work, and downstream savings. Many plans underestimate the true cost of a digital health program by counting only licensing fees. They also overestimate savings when they ignore changes in utilization that would have occurred anyway. Strong ROI methods use comparison groups where possible, control for baseline risk, and include sensitivity analyses. If the vendor presents only a headline savings estimate without showing assumptions, request the workbook and method. That level of transparency should be standard, just as leaders expect clear pricing and scope in other procurement contexts, including call scoring and agent-assist systems.

Track performance by time to value

Population health programs often die when leaders expect immediate savings from interventions that need time to mature. A vendor should be able to state how quickly engagement, adherence, and outcome changes should appear and what lag is expected before financial effects show up. This matters because plans may need to renew, expand, or sunset a program based on evidence rather than hope. The best contracts include milestone-based reviews so both sides know when decisions will be made. If a product is truly valuable, it should survive an honest time-to-value assessment.

Evaluation domain	What to ask	What strong evidence looks like	Common red flag
Clinical validation	What trials or studies support the claim?	Comparative evidence in a similar population	Only testimonials or pre-post charts
Equity impact	Who is excluded or underperforming?	Subgroup reporting with accessibility design	Overall averages only
Interoperability	How does data move across systems?	Standards-based integration and clear workflow fit	Manual exports as the main process
AI safety	How is model drift monitored?	Validation, override logic, and escalation paths	Opaque scoring with no documentation
ROI measurement	What is the baseline and attribution method?	Pre-specified outcomes with comparison groups	Vague savings claims without methods

8) Put Contract Guardrails Around Data, Performance, and Exit

Own the data and define usage rights

Data ownership terms should be explicit. Health plans need to know whether they can export raw data, retain member-level history, use de-identified data for analytics, and recover data on termination. Contracts should specify permissible uses, retention periods, and restrictions on secondary monetization. If the vendor intends to improve its product using client data, that should be disclosed and negotiated, not assumed. When data rights are vague, organizations often discover too late that their own program data have limited portability.

Write performance clauses with measurable triggers

Performance guarantees should be tied to measurable deliverables, not marketing promises. Contracts may specify implementation milestones, uptime thresholds, response times for support issues, data refresh cadence, and minimum reporting requirements. For outcome-based arrangements, the parties should agree on the denominator, attribution method, exclusions, and review cadence before launch. If a vendor is unwilling to define these terms, the plan is accepting financial and operational ambiguity. In other sectors, leaders have learned the value of transparent terms through guides like what’s actually included before paying—healthcare deserves even more precision.

Plan for offboarding from day one

Exit planning is part of risk management, not pessimism. The contract should define how data will be returned, in what format, how long transition support will last, and what happens to unresolved claims, messages, or care pathways. Leaders should also consider continuity of care if a member is mid-intervention when a contract ends. A vendor that resists clear offboarding terms may be creating lock-in rather than value. Strong population health programs are designed to survive vendor turnover without losing clinical continuity or analytical integrity.

9) Use a Pilot Design That Produces Decision-Grade Evidence

Choose a pilot size that can answer the question

A pilot is only useful if it is designed to learn something specific. Too small, and the findings are noisy. Too broad, and the organization spends months implementing a tool without a clear decision framework. Select a pilot population that is large enough to show meaningful differences, but narrow enough to fit operationally. If possible, include a comparator group or staged rollout so the team can assess incremental impact rather than just absolute change.

Measure adoption, workflow burden, and clinical effect together

Decision-grade pilots should examine three layers: member adoption, staff burden, and downstream outcomes. A digital tool that members like but staff cannot support will not scale. A tool that reduces staff work but fails to improve member outcomes may be a process improvement rather than a population health intervention. The pilot should also record unintended effects such as alert fatigue, duplicate outreach, or confusion about care pathways. That is how leaders get beyond vanity metrics and into implementation reality.

Use lessons from adjacent industries to reduce noise

In other sectors, teams learn to validate performance in the field rather than in the brochure. A software launch that breaks workflows is handled like an incident review, not a branding exercise. The same principle applies to digital health. Leaders can draw useful habits from operational playbooks such as digital twin maintenance models, which emphasize monitoring, early failure detection, and controlled adjustments. In healthcare, that discipline improves both safety and scalability.

10) A Practical Checklist for Population Health Leaders

Use this list before you sign

The checklist below converts the evaluation framework into a workable procurement tool. It is intentionally practical and meant to be used by clinical, operational, finance, and IT stakeholders together. A vendor should not advance unless it clears the core gates and meets your organization’s minimum acceptable threshold. When teams use a checklist consistently, they reduce bias, speed decisions, and avoid repeated mistakes. The goal is not to reject innovation; it is to select innovation that can survive real-world scrutiny.

Pro tip: If a vendor cannot explain its evidence, equity strategy, integration pathway, and measurement plan in one meeting, it is not ready for scale.

Decision checklist

Is the target population and use case clearly defined?
Does the clinical evidence match the product’s claims and intended users?
Are subgroup outcomes available by race, language, disability, age, and geography?
Does the product fit your interoperability and security standards?
Can the vendor validate performance using your data or a close proxy population?
Are AI model inputs, outputs, retraining, and override paths documented?
Can the tool operate in low-bandwidth, multilingual, and accessible formats?
Are baseline metrics, attribution methods, and time-to-value defined upfront?
Do contract terms protect data ownership, reporting, and offboarding?
Is there a rollback plan if adoption, equity, or outcomes fall short?

Leaders who want to sharpen their review process can also borrow tactics from procurement-focused SEO blueprints and metrics-driven market analysis, because the underlying lesson is the same: define the decision criteria before you evaluate the option.

Frequently Asked Questions

What is the difference between a digital therapeutic and a general health app?

A digital therapeutic is typically designed to prevent, manage, or treat a medical condition and often requires stronger clinical evidence than a general wellness app. General health apps may focus on education, coaching, reminders, or habit formation without making treatment claims. For payers, the key distinction is not only the label but the claim the vendor makes and the evidence supporting that claim. If a product says it improves depression, diabetes control, or adherence, the evaluation should reflect that medical claim. That is why the clinical bar must match the risk and intended use.

How should payers evaluate ROI if the tool affects multiple outcomes?

Start by selecting one primary outcome and a limited set of secondary measures before implementation. Then define the measurement window, comparison group, and cost categories in advance. If the tool affects admissions, pharmacy adherence, and staff time, each effect should be measured separately and then combined only after the method is clear. Otherwise, the program may appear successful because one benefit is counted while another cost is ignored. Decision-grade ROI should be transparent enough for finance, clinical, and operational leaders to review together.

What evidence should vendors provide for health equity?

Vendors should provide subgroup data, usability testing results, language access capabilities, accessibility features, and a clear description of who may be excluded by design. Ideally, they should also show whether outcomes differ across populations with different levels of digital access or social risk. A credible equity strategy includes more than a diversity statement. It shows that the product was built, tested, and measured with underserved users in mind. If a vendor cannot produce this information, the plan should treat equity claims as unproven.

How much interoperability is enough?

Enough interoperability is whatever is needed to support your workflow without creating manual rework. For some programs, that means bidirectional EHR integration and automated event routing. For others, it means secure claims feeds and exportable analytics. The real test is whether the tool can operate within your existing processes and still produce reliable, actionable data. If the staff must manually reconcile records or rekey information, the integration is probably insufficient for scale.

What contract terms matter most?

The most important terms are data ownership, reporting obligations, performance milestones, privacy and security requirements, support response times, and termination/offboarding provisions. Payers should also clarify whether they can use the data for internal analytics, whether the vendor can reuse client data, and what happens if the vendor misses agreed-upon service levels. A good contract converts operational expectations into enforceable language. Without those guardrails, the plan absorbs risk while the vendor keeps flexibility.

Bottom Line: The Best Digital Health Vendors Make Their Value Verifiable

Payers do not need more digital health hype. They need tools that can demonstrate clinical validity, improve access without widening inequities, fit current workflows, and produce measurable value under real operating conditions. The strongest evaluation process treats vendors like strategic partners and subject them to the same evidence-based scrutiny used for other population health investments. That means asking hard questions early, measuring the right outcomes, and writing contracts that protect the organization if performance falls short. Health plans that adopt this approach will make better decisions, move faster with less risk, and support members with interventions that are more likely to work.

For leaders building a stronger evaluation function, it may also help to study adjacent operational frameworks such as AI supply-chain risk management, feedback-loop design, and metric-driven storytelling. The lesson across all of them is consistent: good decisions come from clear criteria, disciplined measurement, and explicit accountability. In digital health procurement, that is how payers separate promising technology from durable population health value.

Interoperability First: Engineering Playbook for Integrating Wearables and Remote Monitoring into Hospital IT - A deeper look at connecting digital tools to clinical workflows.
Is LED light therapy right for your care recipient? Evidence, indications, and safe home use - A useful example of matching evidence to consumer-facing health claims.
Adaptive Learning Tools for Science Education: Bridging Accessibility Gaps - A parallel framework for designing inclusive digital experiences.
Predictive maintenance for websites: build a digital twin of your one-page site to prevent downtime - A practical model for monitoring failure before scale.
Mitigating the Risks of an AI Supply Chain Disruption - Helpful guidance for vendors and buyers managing AI-related operational risk.

Jordan Ellis

Senior Clinical Content Strategist

Senior editor and content strategist. Writing about technology, design, and the future of digital media. Follow along for deep dives into the industry's moving parts.